News

Polypharmacy, defined as ≥5 concomitant drugs, was significantly higher in patients with psoriatic arthritis when compared with controls (49% vs 17%, respectively).

Adult patients with traumatic brain injury-induced fibromyalgia were randomized 1:1 to receive hyperbaric oxygen therapy or pharmacological intervention.

Results demonstrate that guselkumab was well-tolerated in studies continuing for 1 to 2 years among patients with active psoriatic arthritis regardless of TNFi experience.

Higher baseline Disease Activity Index for Psoriatic Arthritis (DAPSA) was associated with reduced probability of achieving low disease activity or remission.

Results of a recent study showed that the risk of pneumocystis jiroveci pneumonia (PJP) is low in patients with giant cell arteritis (GCA) and polymyalgia rheumatica (PMR), therefore discouraging the routine prescribing of PJP prophylaxis for this patient population.

New pooled data from DISCOVER-1 and DISCOVER-2 show the injection biologic provided full resolution of dactylitis in three-fourths of patients by week 52.

Dialysis-dependent patients in the US with gout have an increased risk of cardiovascular comorbidities, hospitalization, and mortality. Results emphasize the need for improved treatments to enhance outcomes for this patient population.

A cohort analysis from Norway suggests women with active psoriatic arthritis or axial spondylitis are at greater risk of either elective or emergency delivery procedures.

An international pilot study shows a probiotic candidate may improve both management of gout and relevant blood serum levels in treated patients.

New cohort analysis data show women with fibromyalgia are at an increased risk of depression—which is also correlated with a worse life expectancy over 8 years.

Disease activity and burden were higher in patients with rheumatoid arthritis with Medicaid or Medicare coverage, African American patients, and those residing in Southern regions.

A brief increase in venous thromboembolism (VTE) was reported within 30 days after a hospitalization or primary care visit for gout flare. The highest incidence occurred during the 16-30 day period after the flare.

Radiographic non-progressors treated with guselkumab achieved patient-reported minimal disease activity criteria of minimal pain and normalized physical function more often than radiographic non-responders.

Compared with the control group, patients in the exercise for wellbeing (Qi Gong) and physiotherapy groups reported statistically significant improvements at week 5 in joint range of movement, muscle strength, spirometry, and quality of life.

Improvements may be due in part to the association between weight loss and fewer pain symptoms in patients with fibromyalgia.

The approval was based on positive results from the Phase 3 SAPHYR trial, which showed that nearly 3 times more patients achieved sustained remission with sarilumab when compared with placebo.

Results of a recent review showed that adalimumab, etanercept, golimumab, and infliximab are effective and well-tolerated treatments options for patients with juvenile idiopathic arthritis.

Nipocalimab, a FcRn blocker, significantly improved symptoms and reduced immunoglobulin autoantibody levels in patients with myasthenia gravis.

Multivariable models indicated that improvements in the physical component score and mental component score could be predicted by better self-efficacy scores in patients with systemic lupus erythematosus.

Patients with juvenile idiopathic arthritis were at a greater risk of developing autoimmune thyroid disease if they were female, reported ANA and/or RF positivity, and a family history of thyroid disease.

Investigators evaluated the link between gout and thalassemia using data from Taiwan's Longitudinal Health Insurance Database 2000 (LHID 2000).

Study results are the first to demonstrate that tofacitinib may be an effective treatment option for Chinese patients with active psoriatic arthritis.

Of the 23 biomarkers identified in patients with gouty arthritis and hyperuricemia, kynurenic acid, thymine, and phosphatidylinositol (PI) differed from previous gout research.

Patients' perceptions of the effectiveness and necessity of allopurinol for gout treatment proved to be strong factors influencing intentional adherence.

Ginger Hultin, MS, RDN, explained the benefits of an anti-inflammatory nutrition plan for patients living with rheumatic and autoimmune conditions, as well as what rheumatologists need to know.

An analysis of the DELIVER and DAPA-HF trials provides an overview of the impact of gout on heart failure outcomes and effects of dapagliflozin in this patient population.

Investigators identify a strong association between exposure to air pollution and bone mineral loss in postmenopausal women.

Compared with treatments like allopurinol, nanoparticles can improve the biocompatibility and bioavailability while reducing toxicity and side effects in patients with gout.

Guselkumab, an interleukin-23 inhibitor, demonstrated sustained improvements in both TNF-naïve and TNF-experienced patients with psoriatic arthritis.

Data from the phase 2 CLUE trial provide insight into the safety and efficacy of tigulixostat as a serum urate-lowering therapy in patients with gout with hyperuricemia.